Ibrutinib in combination with obinutuzumab for the treatment of chronic lymphocytic leukaemia/small lymphocytic lymphoma in elderly – first line

The combination of ibrutinib (oral capsules) and obinutuzumab (intravenous injection) is being developed as a new treatment option for CLL/SLL in elderly patients. Both drugs act in different unique ways to improve the body’s natural defence to fight the cancer cells and their combined effect may significantly reduce symptoms of the disease and increase survival.